HDAC9 and neoplasm: Additionally, drugs such as lenvatinib, a multikinase inhibitor; panobinostat, an histone deacetylases (HDAC) inhibitor; and mTOR inhibitors target methylation-driven pathways, showing synergistic effects with immunotherapy by inhibiting tumor-promoting pathways like angiogenesis and cell proliferation.